Ethylenediamine

CAS RN:107-15-3

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) Ethylenediamine (EDA) is an eye and mucous membrane irritant and skin sensitizer. EDA hypersensitivity is common, particularly in patients with contact dermatitis.
    • B) EDA hypersensitivity reactions can occur following administration of aminophylline to patients previously sensitized by topical or inhalation routes. Skin reaction can be local, generalized, or exfoliative and may be accompanied by bronchospasm.
    • C) Patients allergic to aminophylline may safely be given other theophylline preparations, but should avoid compounds closely related to EDA such as hydroxyzine.
    • D) Poisoning may occur following inhalation, dermal, and oral exposure.
    • E) When heated to decomposition, ethylenediamine emits toxic fumes of oxides of nitrogen and ammonia.
0.2.3 VITAL SIGNS
  • 0.2.3.1 ACUTE EXPOSURE
    • A) Hypotension has been reported in experimental animals.
0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) Liquid splash may produce acute pain and serious eye injury. Vapor exposure may produce corneal edema causing halos to be seen around lights. Inhalation may cause irritation of respiratory mucosa.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) Hypersensitivity reactions including bronchospasm have occurred.
    • B) Shortness of breath and rhinitis may be noted following inhalation exposure.
  • 0.2.6.2 CHRONIC EXPOSURE
    • A) Bronchospasm, asthma, lung congestion, and pulmonary edema may be seen.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) Headache and dizziness may occur following inhalation exposure.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) Nausea and vomiting have been reported following inhalation exposure.
0.2.9 HEPATIC
  • 0.2.9.1 ACUTE EXPOSURE
    • A) Hepatic injury has been reported from repeated vapor exposures in experimental laboratory animals.
0.2.10 GENITOURINARY
  • 0.2.10.1 ACUTE EXPOSURE
    • A) Renal damage has been reported from repeated vapor exposures in experimental laboratory animals.
0.2.13 HEMATOLOGIC
  • 0.2.13.1 ACUTE EXPOSURE
    • A) Methemoglobinemia has been reported following exposure to maximum allowable concentrations.
  • 0.2.13.2 CHRONIC EXPOSURE
    • A) Methemoglobinemia has been reported.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) Localized contact dermatitis, exacerbation of topically-induced contact dermatitis, generalized maculopapular, erythematous, pruritic, burning dermatitis, and exfoliative dermatitis have been reported.
    • B) Hair loss was reported in experimental laboratory animals from repeated vapor exposures.
  • 0.2.14.2 CHRONIC EXPOSURE
    • A) Hair loss was reported in experimental animals from repeated vapor exposures. Methemoglobinemia has been reported after dermal absorption.
0.2.18 PSYCHIATRIC
  • 0.2.18.1 ACUTE EXPOSURE
    • A) Aggressive behavior has been reported following administration of aminophylline.
0.2.19 IMMUNOLOGIC
  • 0.2.19.1 ACUTE EXPOSURE
    • A) EDA is a skin and respiratory sensitizer.
0.2.20 REPRODUCTIVE HAZARDS
  • A) At the time of this review, no data were available to assess the potential effects of exposure to this agent during pregnancy or lactation.
  • B) No information about possible male reproductive effects in humans was found in available references at the time of this review.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS107-15-3 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
  • 0.2.21.3 ANIMAL OVERVIEW
    • A) No evidence of carcinogenicity was produced by dermal application in laboratory animals.
0.2.22 GENOTOXICITY
  • A) No positive effect on unscheduled DNA synthesis was noted in experimental studies. Mutations have been observed in S typhimurium but not in the Chinese hamster ovary mutation assay. A dose-related effect in the sister chromatid exchange test has not been noted.
0.2.23 OTHER
  • 0.2.23.1 ACUTE EXPOSURE
    • A) Cross reactions with other compounds have been suggested.
The information contained in the Truven Health Analytics Inc. products is intended as an educational aid only. All treatments or procedures are intended to serve as an information resource for physicians or other competent healthcare professionals performing the consultation or evaluation of patients and must be interpreted in view of all attendant circumstances, indications and contraindications. The use of the Truven Health Analytics Inc. products is at your sole risk. These products are provided "as is" and "as available" for use, without warranties of any kind, either express or implied. Truven Health Analytics Inc. makes no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the productsAdditionally, Truven Health ANALYTICS INC. makes no representation or warranties as to the opinions or other service or data you may access, download or use as a result of use of the Truven Health ANALYTICS INC. products. All implied warranties of merchantability and fitness for a particular purpose or use are hereby excluded. Truven Health Analytics Inc. does not assume any responsibility or risk for your use of the Truven Health Analytics Inc. products.
Find more information on this substance at: Hazardous Substances Data Bank , TOXMAP , TOXNET , PubMed